Gay parenting → Egg donor

Choosing an egg donor responsibly.

The terminology that carries real meaning, what screening does and does not cover, the identity and records decisions you make at consent, and how to plan a donor route around the family you actually want.

Intended fathers discussing egg-donor options with a counselor.

The short answer

Choose the identity category deliberately, confirm which screening system a program means when it says “screened,” keep a durable copy of the records your child may need as an adult, and size the donor route around your family goal rather than around one transfer.

Updated July 29, 2026 · Reviewed by Patriot Conceptions Clinical Review Team

On this page TerminologyScreeningIdentity & disclosureRecordsFresh vs frozenFamily sizeAsk the program

Terminology

Say what you actually mean by “donor”

The words a program uses tell you how candid it is about what your child may be able to learn later. Three categories do real work. One popular word does not.

A directed donor is known to you at the time of donation — a friend, a relative of one father, or someone you identified yourself. A nondirected donor is selected through a program without a pre-existing personal relationship. An identity-release arrangement means identifying information may be released under conditions agreed in advance, often when the donor-conceived person reaches a stated age.

The category you choose is not only a preference. It shapes consent documents, what the program is obliged to retain, what you can tell your child at each age, and what happens if someone matches on a consumer DNA site fifteen years from now. Settle it before you sign, because retrofitting an identity arrangement after a birth is far harder than choosing one before a cycle.

The three categories that carry real meaning. Ask the program to state which one applies in writing, and to describe the identity discovery you should realistically expect regardless.
CategoryWhat it meansWhat to confirm in writing
Directed / identifiedThe donor is known or identifiable to you at donation.Consent scope, counseling for both sides, legal review of the relationship, and how medical updates travel later.
Nonidentified at donationIdentifying information is not exchanged at the outset. Later discovery can still occur.Exactly what is withheld, what is retained, and by whom — plus what the program does if a match happens anyway.
Identity-releaseIdentifying information may be released under specified conditions and timing.The trigger age or condition, who holds the release obligation, and what happens if the program ceases to operate.

Screening

What screening covers, and what it cannot rule out

Two different systems are at work: a federal eligibility determination focused on communicable disease, and broader professional recommendations covering history, psychosocial evaluation and genetics. They are not the same thing, and programs sometimes blur them.

Egg and sperm donors require screening and testing under applicable FDA rules and professional guidance. The FDA framework is a regulatory eligibility determination about communicable-disease risk. Professional guidance from ASRM goes further, recommending medical and family-history review, psychosocial evaluation, and genetic carrier screening. When a program says a donor is “fully screened,” ask which system it means and which steps are actually complete.

Current ASRM guidance recommends cystic fibrosis, spinal muscular atrophy, and thalassemia and other hemoglobinopathy screening for all egg and sperm donors, with Fragile X considerations for egg donors, and a preference for pan-ethnic expanded panels over ethnicity-based ones. Ideally the egg source and the sperm source are screened on comparable panels — or the differences are reconciled by a genetic counselor rather than left in two unrelated PDFs.

Genetic screening reduces risk. It does not eliminate it. No panel covers every condition, panels change version to version, and a normal result is a statement about tested conditions, not a prediction about a child.

  • Which genetic panel and which version was run — and on what date?
  • Was the same panel, or a comparable one, run on the intended father whose sperm will be used?
  • Who reconciled the two results, and is that reconciliation in writing?
  • What infectious-disease and FDA eligibility work is complete, and what is still outstanding?
  • What medical and family history was collected, who verified it, and how is it updated if the donor learns something new?
  • Was a psychosocial evaluation completed, and by whom?
  • How are repeat donations across programs monitored?

Identity & disclosure

Decide the identity questions before consent

Disclosure is not a conversation you schedule for later. It is a set of decisions made now, at consent, that determine what is available to your child at every age afterward.

ASRM strongly encourages age-appropriate disclosure to donor-conceived people about the fact of donor conception. Parents retain the decision and the responsibility, but the professional guidance is not ambiguous, and early ordinary family storytelling generally avoids a single dramatic reveal later. Children raised with the fact from the beginning tend to encounter it as background, not as news.

For two fathers, the disclosure conversation has more roles in it than most donor-conception guidance assumes. Your child will eventually distinguish the egg donor, the gestational carrier, the genetic father and the non-genetic father. Keeping those roles distinct in your own language from the start makes the later conversations simpler, and it avoids collapsing three different people into one vague helper.

Curiosity about origins is common and is not a rejection of you. Plan for it the way you plan for anything else foreseeable: decide in advance what information exists, who holds it, and under what conditions it becomes available.

  • Directed, identity-release, or nonidentified at donation — and does everyone signing understand the difference?
  • What contact, if any, is expected between the donor and the two of you during and after the cycle?
  • What route exists for the child to ask questions or seek contact later, and at what age?
  • Whether donor-sibling information or a registry is available, and who maintains it.
  • How significant medical updates travel in both directions, years after the cycle.
  • Who permanently stores genetic and medical history — and what happens if that organization closes.
  • What you will tell your child, in what words, at roughly what ages.

Records

Treat the records as a lifelong family asset

Donor and treatment records carry long-term importance for medical history, identity questions and your child’s own interests. Most families think about them once, at the wrong time — years later, when someone needs them.

Ask for a durable, exportable copy of everything below, held by you, in a format you can still open in two decades. A child’s access to their own medical and genetic history should not depend on whether a particular agency, bank or clinic is still trading on their eighteenth birthday.

  • Donor profile and the consent category that was agreed.
  • Family and medical history, with the date it was last updated.
  • Genetic carrier-screening results, including the panel name and version.
  • Infectious-disease testing and eligibility documentation for the cycle.
  • Clinic and tissue records, including lot identifiers where relevant.
  • Embryo creation, storage and transfer records.
  • Parentage and birth documents.
  • Significant medical updates received from the donor program after the cycle.
  • Contact preferences, and any changes to them over time.

Fresh vs frozen

Fresh cohort or frozen lot

Neither route is better in the abstract. They differ in what they make predictable, and two fathers often need a larger cohort than a single-transfer plan assumes.

Trade-offs to discuss with your clinic. Ask for the clinic’s own thaw, fertilization and blastocyst experience with the specific bank and lot size you are considering, rather than a general figure.
ConsiderationFresh donor cycleFrozen donor lot
Cohort sizeCan produce a larger cohort from one retrievalSold in fixed lots; more than one may be needed
PredictabilityYield depends on stimulation responseUnit count is known before you buy
TimingRequires synchronizing donor, clinic and lab schedulesGenerally faster to start
Splitting between two fathersA larger cohort gives more room to splitMay require multiple lots to split meaningfully
Cancellation exposureA cycle can be cancelled or yield fewer eggs than hopedThaw survival and fertilization still carry uncertainty
Sibling planningEasier to reserve from a single retrievalReserve additional lots early; availability is not open-ended

Family size

Work backward from the family you want

The most common planning mistake is buying the minimum needed for one transfer. If you hope for two or three children, that decision is made at the donor stage, not after the first birth.

Eggs may be divided between two sperm sources to create separate embryo cohorts, subject to egg number, laboratory protocol and clinical judgment. Equal allocation and equal embryo yield are not something any clinic can promise. Build your plan so that an uneven result is disappointing rather than derailing.

Start from the number of children

Two or three children implies more transfers, more attrition and more storage than a single-child plan. Model the whole arc with your clinic before you choose a donor route.

Model family size →

Decide splitting before the retrieval

If both fathers want to create embryos, the allocation approach, reporting and cost need to be agreed with the lab in advance — not improvised on the morning of fertilization.

Plan the embryo strategy →

Reserve for siblings early

Holding eggs or embryos from the first donor process is usually simpler and cheaper than recruiting a donor again years later. Donor availability for a repeat cycle is never guaranteed.

Name your tolerance for repeating

Ask yourselves plainly how many donor cycles you are willing and able to go through, financially and emotionally. Deciding that in advance keeps a disappointing result from becoming a crisis.

Ask the program

Questions a good donor program answers plainly

You are not being difficult. A program that handles these calmly is showing you how it will behave when something goes wrong.

  • Is this donor directed, identity-release, or nonidentified at donation?
  • What identity discovery should we realistically expect later, regardless of category?
  • Who verified the profile claims, and on what date?
  • How many prior cycles and known births are there?
  • Is the donor currently available, and for what window?
  • What ovarian-reserve and prior-cycle information exists?
  • Which genetic panel and version was used, and how is family history updated?
  • What infectious-disease and FDA eligibility work is complete?
  • What are the compensation, travel, legal and cancellation terms?
  • Can the donor communicate with us, or with the child, later — and under what conditions?
  • Are donor-sibling numbers or reporting available?
  • Who retains the records long term?
  • What happens if the retrieval is cancelled or yields no usable eggs?

Common questions.

No program can promise that. A donor may be nonidentified at the time of donation, but DNA databases, relatives who test, records and ordinary internet research can make identity discoverable later. Use precise categories — directed, identity-release, or nonidentified at donation — and plan for age-appropriate disclosure and future contact questions.
Current ASRM guidance recommends cystic fibrosis, spinal muscular atrophy, and thalassemia and other hemoglobinopathy screening for all egg and sperm donors, with Fragile X considerations for egg donors and a preference for pan-ethnic expanded panels. That is separate from the FDA communicable-disease eligibility determination. Ask which panel and version was used, and whether the sperm source was screened comparably.
Not automatically. What matters is the reproductive risk when her results are paired with the sperm source, and whether you receive real genetic counseling on that pairing. Screening reduces risk rather than removing it, so a normal result is a statement about the conditions tested, not a guarantee about a child.
It depends on what you need to be predictable. A fresh cycle can produce a larger cohort from one retrieval, which gives more room to split between two fathers or reserve for siblings, but yield depends on stimulation response. Frozen lots have a known unit count and generally start faster, though more than one lot may be needed. Ask your clinic about its own experience with the specific bank and lot size.
Work backward from the family goal with your clinic rather than buying the minimum for one transfer. Model expected yield or lot size, allocation between two fathers, embryo attrition, storage, and whether the donor would be available for a repeat cycle. Eggs may be divided between two sperm sources subject to egg number, lab protocol and clinical judgment, but equal allocation and equal yield are never guaranteed.
ASRM strongly encourages age-appropriate disclosure about the fact of donor conception, and parents retain the decision. Most families find that ordinary, early storytelling in age-appropriate layers works better than a single later conversation. Keep the roles distinct — egg donor, gestational carrier, parent — and keep a durable record of the donor information your child may want as an adult.
Sources

Key statements on this page link to public sources and the date we last checked them.

Next step

Bring your family-size goal to the donor conversation, not just a profile you liked.

The donor decision sets your embryo strategy, your sibling options and what your child can learn later. It is worth an hour of planning before you shortlist anyone.

Start planning